Cytek Biosciences, Inc. (CTKB)
NASDAQ: CTKB · Real-Time Price · USD
4.220
-0.090 (-2.09%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Cytek Biosciences Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 545 | 649 | 839 | 1,192 | 1,382 | 2,183 | |
Market Cap Growth | 21.20% | -22.58% | -29.66% | -13.74% | -36.68% | - |
Enterprise Value | 310.24 | 402.22 | 569.29 | 940.84 | 1,056 | 1,819 |
Last Close Price | 4.22 | 5.05 | 6.49 | 9.12 | 10.21 | 16.32 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | - | - | 510.50 | - |
Forward PE | 172.84 | 89.56 | 26.14 | 245.06 | 44.39 | 152.95 |
PEG Ratio | - | 1.34 | 1.34 | 1.34 | - | - |
PS Ratio | 2.67 | 3.22 | 4.18 | 6.18 | 8.43 | 17.06 |
PB Ratio | 1.66 | 1.90 | 2.12 | 3.03 | 3.25 | 5.39 |
P/TBV Ratio | 1.83 | 2.09 | 2.36 | 3.49 | 3.44 | 3.41 |
P/FCF Ratio | - | - | 38.37 | 1883.29 | - | 8205.99 |
P/OCF Ratio | - | - | 33.04 | 225.74 | - | 471.45 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 1.52 | 2.00 | 2.84 | 4.87 | 6.44 | 14.21 |
EV/EBITDA Ratio | - | - | - | - | 273.87 | 174.87 |
EV/EBIT Ratio | - | - | - | - | - | 198.59 |
EV/FCF Ratio | - | - | 26.05 | 1486.31 | - | 6836.54 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.04 | 0.04 | 0.02 | 0.03 | 0.03 | 0 |
Debt / EBITDA Ratio | - | - | - | - | 3.78 | - |
Debt / FCF Ratio | - | - | 0.39 | 17.58 | - | - |
Net Debt / Equity Ratio | -0.76 | -0.72 | -0.68 | -0.64 | -0.77 | -0.90 |
Net Debt / EBITDA Ratio | 7.77 | 8.69 | 26.84 | 13.50 | -84.71 | -35.06 |
Net Debt / FCF Ratio | 26.71 | 28.16 | -12.32 | -396.97 | 14.86 | -1370.74 |
Asset Turnover | 0.45 | 0.42 | 0.40 | 0.38 | 0.33 | 0.37 |
Inventory Turnover | - | - | 2.94 | 1.53 | 1.57 | 1.77 |
Quick Ratio | 3.88 | 4.16 | 5.00 | 5.66 | 7.95 | 11.89 |
Current Ratio | 4.69 | 5.04 | 5.86 | 6.97 | 9.26 | 13.01 |
Return on Equity (ROE) | -10.60% | -18.05% | -1.53% | -2.97% | 0.60% | 1.04% |
Return on Assets (ROA) | -9.32% | -18.74% | -4.36% | -4.25% | -0.72% | 1.37% |
Return on Invested Capital (ROIC) | -48.78% | -81.40% | -16.16% | -17.89% | -5.09% | 17.34% |
Return on Capital Employed (ROCE) | -11.67% | -9.90% | -4.72% | -6.13% | -0.40% | 2.94% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | - | - | - | - | 0.20% | 0.00% |
FCF Yield | - | - | 2.61% | 0.05% | - | 0.01% |
Buyback Yield / Dilution | 1.64% | 2.19% | 3.45% | 2.37% | -69.93% | -150.13% |
Total Shareholder Return | 1.64% | 2.19% | 3.45% | 2.37% | -69.93% | -150.13% |